07:00 , Jun 17, 2013 |  BC Week In Review  |  Company News

Zeria, Astellas sales and marketing update

Astellas launched Acofide acotiamide in Japan to treat functional dyspepsia. The National Health Insurance (NHI) list price is ¥36.20 ($0.37) per 100 mg tablet, which is given thrice daily. Japan's Ministry of Health, Labor and...
07:00 , Apr 1, 2013 |  BC Week In Review  |  Clinical News

Acofide acotiamide regulatory update

Zeria and Astellas said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Acofide acotiamide to treat functional dyspepsia. Astellas said it will launch the drug "promptly" after the price is established by Japan's National...
08:00 , Feb 18, 2013 |  BC Week In Review  |  Clinical News

Acotiamide regulatory update

Astellas said a Japanese advisory committee recommended approval of acotiamide to treat alcohol dependence. The company said a final decision from Japan's Ministry of Health, Labor and Welfare usually occurs 1-2 months after the committee...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Clinical News

Acotiamide: Phase III data

In a double-blind, Japanese Phase III trial in 897 patients, thrice-daily 100 mg oral acotiamide met the co-primary endpoints of significantly improving general impression of FD symptoms as measured by a 7-point Likert scale and...
07:00 , Jul 5, 2010 |  BioCentury  |  Finance

2H10 milestones

2H10 milestones...
08:00 , Mar 8, 2004 |  BioCentury  |  Strategy

The Fuji-Yama merger

The Fuji-Yama merger...